The DOI matches its Crossref record; 1,861 of the 1,959 references it cites were found in a registry or an index; 7 of the 11 sources its claims cite were checked for support.
American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update.
Open accessAbstract
Objective The objective of this clinical practice guideline is to provide updated and new evidence-based recommendations for the comprehensive care of persons with diabetes mellitus to clinicians, diabetes-care teams, other health care professionals and stakeholders, and individuals with diabetes and their caregivers. Methods The American Association of Clinical Endocrinology selected a task force of medical experts and staff who updated and assessed clinical questions and recommendations from the prior 2015 version of this guideline and conducted literature searches for relevant scientific papers published from January 1, 2015, through May 15, 2022. Selected studies from results of literature searches composed the evidence base to update 2015 recommendations as well as to develop new recommendations based on review of clinical evidence, current practice, expertise, and consensus, according to established American Association of Clinical Endocrinology protocol for guideline development. Results This guideline includes 170 updated and new evidence-based clinical practice recommendations for the comprehensive care of persons with diabetes. Recommendations are divided into four sections: (1) screening, diagnosis, glycemic targets, and glycemic monitoring; (2) comorbidities and complications, including obesity and management with lifestyle, nutrition, and bariatric surgery, hypertension, dyslipidemia, retinopathy, neuropathy, diabetic kidney disease, and cardiovascular disease; (3) management of prediabetes, type 2 diabetes with antihyperglycemic pharmacotherapy and glycemic targets, type 1 diabetes with insulin therapy, hypoglycemia, hospitalized persons, and women with diabetes in pregnancy; (4) education and new topics regarding diabetes and infertility, nutritional supplements, secondary diabetes, social determinants of health, and virtual care, as well as updated recommendations on cancer risk, nonpharmacologic components of pediatric care plans, depression, education and team approach, occupational risk, role of sleep medicine, and vaccinations in persons with diabetes. Conclusions This updated clinical practice guideline provides evidence-based recommendations to assist with person-centered, team-based clinical decision-making to improve the care of persons with diabetes mellitus.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
20 Own method · 2 Partly supported · 1 Couldn’t confirm · 1 No basis given · accuracy not yet measured
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“A glucose level ≥200 mg/dL in the presence of hyperglycemia symptoms such as polyuria and polydipsia confirm the diagnosis of DM.”
§ American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Pland—2022 Update > Recommendations and Evidence Bases > Evidence Base 1: How is the diagnosis of DM made and what is the current screening protocol for prediabetes and DM?
What the sources say
- Could not verifycites [6] sourceExperimental — accuracy not yet measured
The Diagnostic testing passage (page unavailable) discusses fasting glucose, HbA1c, C-peptide, and antibody tests for evaluating MODY. Neither it nor the other retrieved passages gives a ≥200 mg/dL glucose threshold with hyperglycemia symptoms for diagnosing diabetes; searches for that threshold and symptom-based criterion found no supporting passage in our copy. (LLM, conf=0.73)
- Could not verify
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The concordance between FPG, 2-hour PG, and A1C is not perfect; thus, the diagnosis of DM requires 2 different (fasting glucose and A1C) abnormal test results, either from the same sample or 2 abnormal results on samples drawn on different days.”
§ American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Pland—2022 Update > Recommendations and Evidence Bases > Evidence Base 1: How is the diagnosis of DM made and what is the current screening protocol for prediabetes and DM?
What the sources say
- Partly supportedcites [3] sourceExperimental — accuracy not yet measured
The paper’s introductory passage says diabetes diagnosis requires confirmation of an elevated glucose or HbA1c result and that two different tests above diagnostic thresholds can provide confirmation. It also says repeating the same test on a later sample is preferred, so two different tests are not required. The Discussion says guidelines were unclear about using two tests from one sample; our copy does not address the quoted exception for symptoms with glucose of at least 200 mg/dL or concordance involving 2-hour PG. (LLM, conf=0.87)
- Partly supportedcites [4] sourceExperimental — accuracy not yet measured
The paper’s opening section says that FPG or 2-hour glucose meets the usual diagnostic criteria when abnormal on more than one occasion, and that classic symptoms with a single random plasma glucose of at least 200 mg/dL are diagnostic. It does not say that confirmation requires two different tests (FPG and A1C), or that two abnormal results from the same sample suffice. Its discussion of test variability supports imperfect reproducibility, but not that specific confirmation rule. (LLM, conf=0.88)
- Partly supportedcites [5] sourceExperimental — accuracy not yet measured
The Discussion reports imperfect agreement among HbA1c, fasting plasma glucose, and 2-hour plasma glucose, and says diabetes diagnosis requires repeated measurement rather than a single test. It does not specify that the two abnormal results must be from different tests, describe the same-sample or different-day options, or state an exception for hyperglycemic symptoms with glucose of at least 200 mg/dL. (LLM, conf=0.88)
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Universal screening is recommended, as selective screening (only in women with risk factors) would miss a significant number of women with GDM and universal screening has been shown to be cost-effective compared with selective screening.”
§ American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Pland—2022 Update > Recommendations and Evidence Bases > Evidence Base 1: How is the diagnosis of DM made and what is the current screening protocol for prediabetes and DM?
What the sources say
- Not matchedcites [9]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Partly supportedcites [50] sourceExperimental — accuracy not yet measured
The Conclusions recommend GDM screening at 24–28 weeks using a 75-g OGTT. The paper does not compare universal screening with risk-factor-based selective screening or report that universal screening is cost-effective; searches for selective screening and cost-effectiveness found no such comparison. (LLM, conf=0.84)
- Not checked — no full text of the sourcecites [51] source
- Not checked — no full text of the sourcecites [52] source
- Not checked — no full text of the sourcecites [53] source
- Partly supportedcites [54] sourceExperimental — accuracy not yet measured
Section 5.2 recommends universal testing because risk-factor-based selective testing has poor sensitivity for detecting GDM. But section 5.4 says there is a lack of good evidence for the cost-effectiveness of universal testing in both high- and low-resource countries; it does not establish that universal screening is cost-effective compared with selective screening. (LLM, conf=0.90)
- Could not verifycites [55] sourceExperimental — accuracy not yet measured
The Conclusions discuss childhood glucose outcomes after maternal GDM, not whether universal screening is recommended. Searches of our copy for selective screening, missed cases, and cost-effectiveness found no passage addressing those claims. (LLM, conf=0.76)
- Not matched
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Real-time CGM (rtCGM) or isCGM is recommended for all persons with T1D, regardless of insulin delivery system, to improve A1C levels and to reduce the risk for hypoglycemia and DKA.”
§ American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Pland—2022 Update > Recommendations and Evidence Bases > Question 3: When and how should glucose monitoring be used?
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“DM is diagnosed by using any of 3 established criteria for elevated blood glucose (BG) concentrations (Table 4). FPG ≥126 mg/dL, 2-hour PG ≥ 200 mg/dL during 75-g OGTT, and A1C ≥ 6.5% are equally appropriate for diagnostic screening (Table 4).”
§ American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Pland—2022 Update > Recommendations and Evidence Bases > Evidence Base 1: How is the diagnosis of DM made and what is the current screening protocol for prediabetes and DM?
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“For most hospitalized persons with hyperglycemia in both the intensive care unit (ICU) and non-ICU settings, a glucose range of 140 to 180 mg/dL is recommended, provided this target can be safely achieved (Table 6).”
§ American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Pland—2022 Update > Recommendations and Evidence Bases > Question 2. What are the glycemic treatment goals for persons with DM?
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Diabetic peripheral neuropathy (DPN) is a clinical diagnosis. A comprehensive differential diagnosis should be considered to rule out nondiabetic neuropathies.”
§ American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Pland—2022 Update > Section 2: Comorbidities and Complications > Question 8: How should neuropathy be diagnosed and managed in persons with DM?
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“All persons who use insulin should use CGM or perform BG monitoring (BGM) a minimum of twice daily and ideally before any insulin injection.”
§ American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Pland—2022 Update > Recommendations and Evidence Bases > Question 3: When and how should glucose monitoring be used?
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“A1C should be measured at least semiannually in all persons with DM and at least quarterly in persons not at their glycemic target.”
§ American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Pland—2022 Update > Recommendations and Evidence Bases > Question 3: When and how should glucose monitoring be used?
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Screening for DPN should be done at diagnosis of T2D, within 5 years of the diagnosis of T1D, and subsequently annually or whenever symptoms occur, by performing a clinical history and physical exam.”
§ American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Pland—2022 Update > Section 2: Comorbidities and Complications > Question 8: How should neuropathy be diagnosed and managed in persons with DM?
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Continuous access to CGM for daily use is suggested for people living with T2DM at higher risk of hypoglycaemia, similar to the current CGM clinical practice guideline recommendations from Diabetes Canada 56 and the American Association of Clinical Endocrinologists. 57”
From Continuous glucose monitoring in noninsulin‐treated type 2 diabetes: A critical review of reported trials with an updated systematic review and meta‐analysis of randomised controlled trials (2025) · cites this paper as [57]
Experimental — accuracy not yet measuredIn the citing paper
“Approximately 2–5 times more patients discontinued orforglipron versus placebo due to adverse events, comparable to other GLP‐1 receptor agonists where 5%–15% discontinue in clinical trials [48].”
From Efficacy and Safety of Orforglipron in Obese Adults With or Without Diabetes: A Systematic Review and Meta‐Analysis (2025) · cites this paper as [48]
In the citing paper
“Current guideline recommendations by the American Diabetes Association (ADA), European Association for the Study of Diabetes (EASD), American College of Sports Medicine (ACSM), American Association of Clinical Endocrinology (AACE), and the American Heart Association (AHA) advocate regular resistance and aerobic exercise, as well as physical activity such as increasing daily steps to avoid sed”
From The Impact of Physical Activity in Patients With Type 2 Diabetes (2025) · cites this paper as [23]
In the citing paper
“AACE and the ADA recommend avoiding no more than 2 to 3 days between exercise routines to maintain improvement in insulin sensitivity.”
From The Impact of Physical Activity in Patients With Type 2 Diabetes (2025) · cites this paper as [23]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated major: it would touch a result — a value a result rests on, reported and recomputed p-values on opposite sides of the significance level, two passages that conflict with no sign which is right, or a cited work retracted before this paper was published.
In the paper
§ American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Pland—2022 Update > Section 2: Comorbidities and Complications > Question 6: How should DKD or CKD in DM be managed?
“An SGLT2i with proven benefit is recommended as foundational therapy for persons with T2D and CKD with eGFR ≥20 mL/min/1.73 m2 to reduce progression of CKD and risk of CVD.”
§ American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Pland—2022 Update > Section 2: Comorbidities and Complications > Evidence Base 6: How should DKD or CKD in DM be managed?
“An SGLT2i with proven kidney protection is recommended for people with T2D who have an eGFR >25 mL/min/1.73 m2 irrespective of albuminuria to reduce risks of DKD or CKD in DM and CVD.425,443–469 In those with HF, one agent in the class, empagliflozin, can be used with an eGFR as low as 20 mL/min/1.73 m2.”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Pland—2022 Update > Recommendations and Evidence Bases > Section 1: Screening, Diagnosis, Glycemic Targets, and Glycemic Monitoring
“The one-step approach uses a 2-hour 75-g oral glucose tolerance test (OGTT) after ≥8 hours of fasting with diagnostic cutoffs of one or more FPG ≥92 mg/dL, 1-hour PG ≥180 mg/dL, or 2-hour PG ≥153 mg/dL.”
§ American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Pland—2022 Update > Section 3: Management of Prediabetes, T2D, and T1D With Selection of Glycemic Targets, Lifestyle Interventions, and Antihyperglycemic Pharmacotherapy (Insulin Therapy for all With T1D and Select Individuals With T2D); Prevention, Identification, and Treatment of Hypoglycemia; Treatment of Hospitalized Persons With DM or Those With Hyperglycemia Without Diagnosis of DM; and Women With GDM > Evidence Base 16: How should DM in pregnancy be managed?
“Glucose criteria diagnostic for GDM are an FPG >92 mg/dL, 1-hour postglucose challenge value ≥180 mg/dL, or 2-hour value ≥153 mg/dL.”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Pland—2022 Update > Section 2: Comorbidities and Complications > Evidence Base 10: How should obesity be managed in persons with DM?
“A phase 2 study in persons with biopsy-proven NASH using a daily injection equivalent to semaglutide 2.4 g/week demonstrated 13% weight loss”
§ American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Pland—2022 Update > Section 2: Comorbidities and Complications > Evidence Base 10: How should obesity be managed in persons with DM?
“Subcutaneous semaglutide at the higher dose of 2.4 mg/week has been approved for chronic weight management”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Pland—2022 Update > Recommendations and Evidence Bases > Section 1: Screening, Diagnosis, Glycemic Targets, and Glycemic Monitoring
“Diagnosis of DM requires 2 abnormal test results, either from the same sample or 2 abnormal results on samples drawn on different days.”
§ American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Pland—2022 Update > Recommendations and Evidence Bases > Evidence Base 1: How is the diagnosis of DM made and what is the current screening protocol for prediabetes and DM?
“the diagnosis of DM requires 2 different (fasting glucose and A1C) abnormal test results, either from the same sample or 2 abnormal results on samples drawn on different days.”
Cited works that were retracted
Works this paper cites that were later retracted, from the retraction notices publishers deposit. Major when the notice came out before this paper was published.
Rated major: it would touch a result — a value a result rests on, reported and recomputed p-values on opposite sides of the significance level, two passages that conflict with no sign which is right, or a cited work retracted before this paper was published.
In the paper
“Adler, 2021, Reprint of: Classification of diabetes mellitus, Diabetes Res Clin Pract, 10.1016/j.diabres.2021.108972”
Cited work 10.1016/j.diabres.2021.108972 · retracted 2021-07-31 · notice 10.1016/j.diabres.2021.108972 · this paper published 2022-10
Citations
Cites
1 retracted
WITHDRAWN: Reprint of: Classification of diabetes mellitus
Adler, A., Bennett, P., Chair, S. C., Gregg, E., Venkat Narayan, K. M., Schmidt, M. I., Sobngwi, E., Tajima, N., Tandon, N., Unwin, N., et al. (2021) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2021.108972 · Cited by 38
Retracted(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291401 · Cited by 24,667
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011
Alberti, K. G. M. M., Eckel, R. H., Grundy, S. M., Zimmet, P. Z., Cleeman, J. I., Donato, K. A., Fruchart, J.-C., James, W. P. T., Loria, C. M., & Smith, S. C. (2009) · Circulation · doi:10.1161/circulationaha.109.192644 · Cited by 14,860
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
Ahmed, A., Jorna, T., & Bhandari, S. (2016) · The Nephron journals/Nephron journals · doi:10.1159/000447068 · Cited by 11,782
Intensive insulin therapy in critically ill patients.
Van den Berghe, G., Wouters, P., Weekers, F., Verwaest, C., Bruyninckx, F., Schetz, M., Vlasselaers, D., Ferdinande, P., Lauwers, P., & Bouillon, R. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011300 · Cited by 9,977
Richardson, S., Hirsch, J. S., Narasimhan, M., Crawford, J. M., McGinn, T., Davidson, K. W., and the Northwell COVID-19 Research Consortium, Barnaby, D. P., Becker, L. B., Chelico, J. D., et al. (2020) · JAMA · doi:10.1001/jama.2020.6775 · Cited by 9,254
Stratton, I. M. (2000) · BMJ · doi:10.1136/bmj.321.7258.405 · Cited by 9,059
Research works printed but not linked: 9
- Gillett, 2009, International Expert Committee Report on the role of the A1C assay in the diagnosis of diabetes: Diabetes care, Clin Biochem Rev, 30, 197
- 1991, VIII. Study design, progress and performance, Diabetologia, 34, 877
- Nußbaumer, 2016, Ezetimibe-statin combination therapy, Dtsch arztebl int, 113, 445
- Whelton, 2018, Hypertens (Dallas. TX, 71, e13
- 2012, KDIGO clinical practice guideline for anemia in chronic kidney disease, Kidney Int Suppl, 2, 279
- Miller, 2015, Erratum. J Fam Pract, 64, 452
- Mechanick, 2019, Endocr Pract, 25, 1346
- 2019, Long-term effects of metformin on diabetes prevention: identification of subgroups that benefited most in the Diabetes Prevention Program and Diabetes Prevention Program Outcomes Study, Diabetes Care, 42, 601, 10.2337/dc18-1970 · DOI · Paper page
- American Diabetes Association. Medical management of pregnancy complicated by diabetes fourth edition. Jovanovic L, ed. Alexandria, VA: American Diabetes Association, 2009.
Cited by
Sorted by citations
Samson, S. L., Vellanki, P., Blonde, L., Christofides, E. A., Galindo, R. J., Hirsch, I. B., Isaacs, S. D., Izuora, K. E., Low Wang, C. C., Twining, C. L., et al. (2023) · Endocrine Practice · doi:10.1016/j.eprac.2023.02.001 · Cited by 375
Self-citationDisorders of lipid metabolism. Clinical Guidelines 2023
Владиславович, Е. М., Kukharchuk, V. V., Сергиенко, И. В., Alieva, A. S., Antsiferov, M. B., Ansheles, A. A., Arabidze, G. G., Dm, A., Arutyunov, G. P., Ахмеджанов, Н. М., et al. (2023) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2023-5471 · Cited by 270
Baricitinib and β-cell function in patients with new-onset type 1 diabetes
Waibel, M., Wentworth, J. M., So, M., Couper, J. J., Cameron, F. J., MacIsaac, R. J., Atlas, G., Gorelik, A., Litwak, S., Sanz-Villanueva, L., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2306691 · Cited by 194
Honarmand, K., Sirimaturos, M., Hirshberg, E. L., Bircher, N. G., Agus, M. S. D., Carpenter, D. L., Downs, C. R., Farrington, E. A., Freire, A. X., Grow, A., et al. (2024) · Critical Care Medicine · doi:10.1097/ccm.0000000000006174 · Cited by 177
Self-citationNadolsky, K., Garvey, W. T., Agarwal, M., Bonnecaze, A., Burguera, B., Chaplin, M. D., Griebeler, M. L., Harris, S. R., Schellinger, J. N., Simonetti, J., et al. (2025) · Endocrine Practice · doi:10.1016/j.eprac.2025.07.017 · Cited by 141
Self-citationCombination therapy for kidney disease in people with diabetes mellitus
van Raalte, D. H., Bjornstad, P., Cherney, D. Z. I., de Boer, I. H., Fioretto, P., Gordin, D., Persson, F., Rosas, S. E., Rossing, P., Schaub, J. A., et al. (2024) · Nature Reviews Nephrology · doi:10.1038/s41581-024-00827-z · Cited by 127
Self-citationAn update on peptide-based therapies for type 2 diabetes and obesity
Bailey, C. J., Flatt, P. R., & Conlon, J. M. (2023) · Peptides · doi:10.1016/j.peptides.2023.170939 · Cited by 111
Adverse Events Related to Tirzepatide
Mishra, R., Raj, R., Elshimy, G., Zapata, I., Kannan, L., Majety, P., Edem, D., & Correa, R. (2023) · Journal of the Endocrine Society · doi:10.1210/jendso/bvad016 · Cited by 110
“GLP-1 receptor agonists (GLP-1 RAs) have been approved for the treatment of T2DM since 2005 and are recommended, as per the latest guidelines, early in the treatment algorithm given the associated weight reduction, glycemic efficacy, and favorable cardio-nephrovascular outcomes [7, 8].”
BackgroundStanciu, S. M., Rusu, E., Miricescu, D., Radu, A. C., Axinia, B., Vrabie, A.-M., Ionescu, R. F., Jinga, M., & Sîrbu, C. A. (2023) · Metabolites · doi:10.3390/metabo13010087 · Cited by 123
Heerspink, H. J. L., Agarwal, R., Bakris, G. L., Cherney, D. Z. I., Lam, C. S. P., Neuen, B. L., Sarafidis, P. A., Tuttle, K. R., Wanner, C., BRINKER, M. D., et al. (2024) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfae132 · Cited by 102
Self-citationThierens, N. D. E., Verdonk, R. C., Löhr, M. J., van Santvoort, H. C., Bouwense, S. A. W., & van Hooft, J. E. (2024) · The Lancet · doi:10.1016/s0140-6736(24)02187-1 · Cited by 98
Nadolsky, K., Addison, B., Agarwal, M., Almandoz, J. P., Bird, M. D., DeGeeter Chaplin, M., Garvey, W. T., & Kyle, T. K. (2023) · Endocrine Practice · doi:10.1016/j.eprac.2023.03.272 · Cited by 86
Self-citationPhillip, M., Achenbach, P., Addala, A., Albanese-O’Neill, A., Battelino, T., Bell, K. J., Besser, R. E. J., Bonifacio, E., Colhoun, H. M., Couper, J. J., et al. (2024) · Diabetes Care · doi:10.2337/dci24-0042 · Cited by 79
Self-citationAdvances in the management of type 2 diabetes in adults
Galindo, R. J., Trujillo, J. M., Wang, C. C. L., & McCoy, R. G. (2023) · BMJ Medicine · doi:10.1136/bmjmed-2022-000372 · Cited by 90
“Many, 6 24 25 although not all, 26 clinical practice guidelines recommend treatment with GLP1RAs or SGLT2is, or both, for patients with cardiovascular or kidney disease, or both, or with risk factors for atherosclerotic cardiovascular disease, independent of glycaemic control, although all continue…”
BackgroundSelf-citationSpectrum of Diabetic Neuropathy: New Insights in Diagnosis and Treatment
Dillon, B. R., Ang, L. P., & Pop‐Busui, R. (2024) · Annual Review of Medicine · doi:10.1146/annurev-med-043021-033114 · Cited by 85
Self-citationRobinson, D. J., Hanson, K., Jain, A. B., Kichler, J. C., Mehta, G., Melamed, O. C., Vallis, M., Bajaj, H. S., Barnes, T., Gilbert, J., et al. (2023) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2023.04.009 · Cited by 73
Patel, S. B., Wyne, K. L., Afreen, S., Belalcazar, L. M., Bird, M. D., Coles, S., Marrs, J. C., Peng, C. C., Pulipati, V. P., Sultan, S., et al. (2025) · Endocrine Practice · doi:10.1016/j.eprac.2024.09.016 · Cited by 80
Self-citationCardiorenal benefits of finerenone: protecting kidney and heart
González‐Juanatey, J. R., Górriz, J. L., Ortíz, A., Valle, A., Soler, M. J., & Fácila, L. (2023) · Annals of Medicine · doi:10.1080/07853890.2023.2171110 · Cited by 83
“The 2022 American Association of Clinical Endocrinology (AACE) guidelines [65] and the 2022 ADA and Kidney Disease: Improving Global Outcomes (KDIGO) joint consensus [66] recommend the use of finerenone in persons with T2D, an estimated glomerular filtration rate 25mL/min/1.”
BackgroundPhillip, M., Achenbach, P., Addala, A., Albanese-O’Neill, A., Battelino, T., Bell, K. J., Besser, R. E. J., Bonifacio, E. E., Colhoun, H. M., Couper, J., et al. (2024) · Diabetologia · doi:10.1007/s00125-024-06205-5 · Cited by 83
Self-citationCurrent barriers to initiating insulin therapy in individuals with type 2 diabetes
Sanz-Pastor, A. G., Enríquez, A. J., Bao, A. S., & Ampudia‐Blasco, F. J. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1366368 · Cited by 82
Guideline for the Management of Diabetes Mellitus in the Elderly in China (2024 Edition)
Guo, L., & Xiao, X. (2024) · Aging Medicine · doi:10.1002/agm2.12294 · Cited by 69
“109 The dosage is adjusted every 3 to 5 days depending on the fasting blood glucose level until the goal is reached.”
BackgroundMechanisms underlying delirium in patients with critical illness
Fan, Y.-Y., Luo, R.-Y., Wang, M., Yuan, C.-Y., Sun, Y., & Jing, J. (2024) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2024.1446523 · Cited by 71
Early detection of type 2 diabetes risk: limitations of current diagnostic criteria
Zhang, J., Zhang, Z., Zhang, K., Ge, X., Sun, R., & Zhai, X. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1260623 · Cited by 87
Petersen, E., Stauss, T. G., Scowcroft, J. A., Jaasma, M. J., Brooks, E. S., Edgar, D. R., White, J. L., Sills, S. M., Amirdelfan, K., Guirguis, M. N., et al. (2023) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2023.110865 · Cited by 59
Dicembrini, I., Silverii, G. A., Clerico, A., Fornengo, R., Gabutti, G., Sordi, V., Tafuri, S., Peruzzi, O., & Mannucci, E. (2023) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2023.03.016 · Cited by 59
Cho, Y. K., & Jung, C. H. (2023) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2023.0072 · Cited by 56
“…of Clinical Endo-crinology mentions diabetes associated with ICIs as one of common forms of secondary diabetes; the guideline recommended that patients on ICI therapy should be monitored closely for early detection and therapy for hyperglycemia and the long-term development of diabetes [75].”
BackgroundPainful Diabetic Peripheral Neuropathy: Practical Guidance and Challenges for Clinical Management
Preston, F., Riley, D. R. J., Azmi, S., & Alam, U. (2023) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s370050 · Cited by 63
“Again, there is negligible evidence for lipid control or lipid lowering therapies to be used therapeutically in PDPN.(12)”
BackgroundInfluentialPrevalence, Cost, and Burden of Diabetic Ketoacidosis
Virdi, N. S., Poon, Y., Abaniel, R. M., & Bergenstal, R. M. (2023) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2023.0149 · Cited by 57
Guirguis, E. H., Dougherty, J., Thornby, K., Grace, Y., & Mack, K. (2024) · Annals of Pharmacotherapy · doi:10.1177/10600280241259528 · Cited by 52
“2,34 While liver biopsy is a cornerstone in MASH diagnosis, it is invasive and expensive.”
Comparative Effectiveness of Second-Line Antihyperglycemic Agents for Cardiovascular Outcomes
Khera, R., Aminorroaya, A., Dhingra, L. S., Thangaraj, P. M., Pedroso Camargos, A., Bu, F., Ding, X., Nishimura, A., Anand, T. V., Arshad, F., et al. (2024) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2024.05.069 · Cited by 47
Mallick‐Searle, T., & Adler, J. A. (2024) · Journal of Pain Research · doi:10.2147/jpr.s442595 · Cited by 49
“18,20,21 Capsaicin 8% topical system, the only FDA approved non-oral pharmaceutical to treat painful DPN, is a first-line treatment option in the AACE guidelines 21 and is recommended in the ADA compendium.”
Chang, M. G., Ripoll, J. G., Lopez, E., Krishnan, K., & Bittner, E. A. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13216336 · Cited by 43
Hagerf, B. V., Protuš, M., Németová, L., Mráz, M., Kieslichová, E., Uchytilová, E., Indrova, V., Lelito, J., Girman, P., Haluzı́k, M., et al. (2024) · Diabetes Care · doi:10.2337/dc23-1663 · Cited by 43
The prediabetes conundrum: striking the balance between risk and resources
Blond, M. B., Færch, K., Herder, C., Ziegler, D., & Stehouwer, C. D. A. (2023) · Diabetologia · doi:10.1007/s00125-023-05890-y · Cited by 33
Zelada, H., Perez‐Guzman, M. C., Cherñavvsky, D. R., & Galindo, R. J. (2023) · Endocrine Connections · doi:10.1530/ec-23-0180 · Cited by 34
Self-citationLindfors, A., Strandberg, R., & Hagström, H. (2024) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(24)00313-3 · Cited by 33
Kelepouris, E., Peter, W. L. S., Neumiller, J. J., & Wright, E. E. (2023) · Diabetes Therapy · doi:10.1007/s13300-023-01416-2 · Cited by 37
Bolt, J., Carvalho, V., Lin, K., Lee, S. J., & Inglis, C. (2024) · Age and Ageing · doi:10.1093/ageing/afae259 · Cited by 39
“This included six CPGs that recommended avoiding long-acting sulfony-lureas [13, 18, 26, 27, 30, 35], three of which suggested short-acting sulfonylureas, if this class of medication is used [26, 27, 30].”
InfluentialFujii, M., Ohno, Y., Ikeda, A., Godai, K., Li, Y., Nakamura, Y., Yabe, D., Tsushita, K., Kashihara, N., Kamide, K., et al. (2023) · Hypertension Research · doi:10.1038/s41440-023-01185-2 · Cited by 36
Zuidema, X., van Daal, E., van Geel, I., de Geus, T. J., van Kuijk, S. M. J., de Galan, B. E., de Meij, N., & Zundert, J. H. M. V. (2022) · Neuromodulation Technology at the Neural Interface · doi:10.1016/j.neurom.2022.12.003 · Cited by 33
Esposito, S., Rosafio, C., Antodaro, F., Argentiero, A., Bassi, M., Becherucci, P., Bonsanto, F., Cagliero, A., Cannata, G., Capello, F., et al. (2023) · Journal of Personalized Medicine · doi:10.3390/jpm13020235 · Cited by 34
Mechanisms and clinical applications of incretin therapies for diabetes and chronic kidney disease
Alicic, R. Z., Neumiller, J. J., & Tuttle, K. R. (2023) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0000000000000894 · Cited by 33
Self-citationSayed, D., Deer, T. R., Hagedorn, J. M., Sayed, A., D'Souza, R. S., Lam, C. M., Khatri, N., Hussaini, Z., Pritzlaff, S. G., Abdullah, N. M., et al. (2024) · Journal of Pain Research · doi:10.2147/jpr.s451006 · Cited by 33
Design and rationale of FINE-REAL: A prospective study of finerenone in clinical practice
Desai, N. R., Navaneethan, S. D., Nicholas, S. B., Pantalone, K. M., Wanner, C., Hamacher, S., Gay, A., & Wheeler, D. C. (2023) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2023.108411 · Cited by 29
Karpov, D. S., Sosnovtseva, A. O., Pylina, S. V., Bastrich, A., Petrova, D. A., Kovalev, M. A., Shuvalova, A. I., Константиновна, Е. А., & Mokrysheva, N. G. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242417320 · Cited by 30
“Patients with idiopathic T1D have no autoantibodies, and some patients with LADA or T2D may have some autoantibodies present, making these tests less specific [33].”
BackgroundSahay, R. K., Giri, R., Shembalkar, J., Gupta, S. K., Mohan, B., Kurmi, P. H., Kumar, S., Sawardekar, V. M., Mishra, A., Murthy, L. S., et al. (2023) · Advances in Therapy · doi:10.1007/s12325-023-02523-z · Cited by 30
Aronson, R., Abitbol, A., Bajaj, H. S., Cheng, A. Y. Y., Christopoulos, S., Harris, S. B., Jain, A. B., & Goldenberg, R. M. (2025) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.70008 · Cited by 33
“57”
Wilson, L. M., Herzig, S. J., Marcantonio, E. R., Steinman, M. A., Schonberg, M. A., Wang, B. X., Hileman-Kaplan, E., & Anderson, T. S. (2025) · Diabetes Care · doi:10.2337/dc24-2510 · Cited by 27
Suresh, M. G., Mohamed, S., Geetha, H. S., Prabhu, S., Trivedi, N., Ng, Z. C., Mehta, P. D., Brar, A. S., Sohal, A., Goyal, M. K., et al. (2026) · World Journal of Diabetes · doi:10.4239/wjd.v17.i2.113149 · Cited by 30
Nada, A. A., Metwally, A. M., Asaad, A. M., Çeli̇k, İ., Ibrahim, R. S., & Eldin, S. M. S. (2024) · BMC Complementary Medicine and Therapies · doi:10.1186/s12906-024-04348-x · Cited by 25
“In addition to acarbose’s role in diabetics, according to the American Association of Clinical Endocrinology (AACE) Clinical Practice Guideline, it can be used in the prevention of the progression of prediabetics to Type 2 DM [8].”
BackgroundKalyani, R. R., Allende-Vigo, M. Z., Antinori-Lent, K. J., Close, K. L., Das, S. R., Deroze, P., Edelman, S. V., El Sayed, N. A., Kerr, D., Neumiller, J. J., et al. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad745 · Cited by 25
Chang, M. G., & Bittner, E. A. (2024) · Canadian Journal of Anesthesia/Journal canadien d anesthésie · doi:10.1007/s12630-024-02810-5 · Cited by 25
“ISMP 26 Consider withholding GLP-1 RAs for at least three half-lives prior to the procedure AANA 25 For GLP-1 RAs taken daily, consider withholding on the day of surgery; for GLP-1 RAs taken weekly, consider withholding a week before surgery/procedure The AACE and ADA provided no guidance on this topic According to AS…”
InfluentialJiang, H., Gao, M., Liu, Z., et al. (2024) · IEEE Journal of Biomedical and Health Informatics · doi:10.1109/jbhi.2024.3377592 · Cited by 23
“In clinical practice, doctors systematically monitor notable regions, paying close attention to any suspicious indications of lesions, particularly micro lesions, over an extended period [27], [28], [29].”
Butt, M. D., Ong, S. C., Rafiq, A., Malik, T., Sajjad, A., Batool, N., Chughtai, A. U. H., Wahab, M. U., Abdullah, M., & Babar, Z. (2023) · Scientific Reports · doi:10.1038/s41598-023-50517-2 · Cited by 27
“Metformin is the first-line oral anti-diabetic agent recommended in most guidelines published by the American Association of Clinical Endocrinology and the International Diabetes Federation 10,11 .”
Nicholas, S. B., Correa‐Rotter, R., Desai, N. R., Guo, L., Navaneethan, S. D., Pantalone, K. M., Wanner, C., Hamacher, S., Fatoba, S., Horvat-Broecker, A., et al. (2024) · Journal of Nephrology · doi:10.1007/s40620-024-02070-y · Cited by 24
Honarmand, K., Sirimaturos, M., Hirshberg, E. L., Bircher, N. G., Agus, M. S. D., Carpenter, D. L., Downs, C. R., Farrington, E. A., Freire, A. X., Grow, A., et al. (2024) · Critical Care Medicine · doi:10.1097/ccm.0000000000006173 · Cited by 22
Self-citationChen, W., Zheng, L., Wang, J., Lin, Y., & Zhou, T. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1320603 · Cited by 23
Tian, J., Hu, C., Luo, Y., Zhang, Z., Xiong, S., & Liu, H. (2025) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-025-01626-7 · Cited by 22
Diabetic Cardiomyopathy: What Clinicians Should Know
Smati, H., Qadeer, Y. K., Rodríguez, M., Moras, E., Fonarow, G. C., Isaacs, S. D., Marwick, T. H., & Krittanawong, C. (2024) · The American Journal of Medicine · doi:10.1016/j.amjmed.2024.10.026 · Cited by 24
Elshaer, A., Chascsa, D. M. H., & Lizaola‐Mayo, B. (2024) · Life · doi:10.3390/life14070844 · Cited by 26
“The American Association of Clinical Endocrinologists 2022 Clinical Practice Guidelines for MASLD recommends the initiation of GLP-1 RA for patients with T2DM with biopsy-proven MASH [79].”
BackgroundThe Evolution of Diabetes Technology – Options Toward Personalized Care
Zahid, M., Dowlatshahi, S., Kansara, A., & Sadhu, A. (2023) · Endocrine Practice · doi:10.1016/j.eprac.2023.04.007 · Cited by 22
Self-citationCheng, H., Jia, Z., Li, Y., Yu, X., Wang, J. J., Xie, Y. J., Hernández, J., & Wang, H. (2024) · JMIR Public Health and Surveillance · doi:10.2196/49617 · Cited by 25
“This is in line with recent recommendations from the United States and Europe, advocating that early and sustainable preventative efforts could spare the expense of managing T2DM and its long-term complications [48,49].”
ResultEsposito, S., Rosafio, C., Antodaro, F., Argentiero, A., Bassi, M., Becherucci, P., Bonsanto, F., Cagliero, A., Cannata, G., Capello, F., et al. (2023) · Journal of Personalized Medicine · doi:10.3390/jpm13020198 · Cited by 20
The Black Box Orchestra of Gut Bacteria and Bile Acids: Who Is the Conductor?
Majait, S., Nieuwdorp, M., Kemper, E. M., & Soeters, M. R. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24031816 · Cited by 20
“Western lifestyle including an inactive, sedentary behavior and high-caloric nutritional intake plays a central role in the pathogenesis of T2DM [2].”
BackgroundMottl, A. K., & Nicholas, S. B. (2023) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2023.09.003 · Cited by 27
Perioperative Glycemic Management in Cardiac Surgery: A Narrative Review
Thongsuk, Y., & Hwang, N. C. (2023) · Journal of Cardiothoracic and Vascular Anesthesia · doi:10.1053/j.jvca.2023.08.149 · Cited by 20
Butucă, A., Dobrea, C. M., Arseniu, A. M., Frum, A., Chiş, A. A., Rus, L. L., Ghibu, S., Juncan, A. M., Muntean, A. C., Lazăr, A. E., et al. (2024) · Biomedicines · doi:10.3390/biomedicines12051124 · Cited by 24
“Depending on glycemic status, the glucagon secretion could be increased in normoglycemic or hypoglycemic patients (glucagonotropic effect) or inhibited in hyperglycemic patients (glucagonostatic effect) [22,32,33].”
BackgroundSuárez, M., Gil-Rojas, S., Martínez-Blanco, P., Torres, A., Ramón, A., Blasco-Segura, P., Torralba, M., & Mateo, J. (2024) · Cancers · doi:10.3390/cancers16061114 · Cited by 18
“…demographic variables and comorbidities collected were age, sex, date of HCC diagnosis, date of death or censoring date, active alcohol consumption, active smoking, diagnosis of diabetes mellitus (DM) [26] and dyslipidemia (DL) [27], and obesity (considered as a body mass index ≥ 30 kg/m 2 [28]).”
BackgroundDávila-Rúales, V., Córdoba, L. F. G., Medina, A. M. G., Múñoz, Ó., Serrano, M. N., & Henao, D. C. (2024) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/20420188241304459 · Cited by 20
Galindo, R. J., Moazzami, B., Scioscia, M. F., Zambrano, C., Albury, B. S., Saling, J., Vellanki, P., Pasquel, F. J., Davis, G. M., Fayfman, M., et al. (2023) · Diabetes Care · doi:10.2337/dc22-2426 · Cited by 19
Self-citationBell, D. S. H., McGill, J. B., & Jerkins, T. W. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15181 · Cited by 18
“The 2022 KDIGO guidelines recommend treating patients with T2D and CKD, and an eGFR of less than 20 mL/min per 1.73m2, with an SGLT2 inhibitor.67 The consensus statement is also in favour of administering an SGLT2 inhibitor or glucagon-like peptide-1 receptor agonist to patients with T2D with either established athero…”
BackgroundSelf-citationGlycemic Management and Individualized Diabetes Care in Dialysis-Dependent Kidney Failure
Klein, K. R., Lingvay, I., Tuttle, K. R., & Flythe, J. E. (2024) · Diabetes Care · doi:10.2337/dci24-0081 · Cited by 22
Self-citation4. Painful diabetic polyneuropathy
Zuidema, X., de Galan, B. E., Brouwer, B. A., Cohen, S. P., Eldabe, S. S., Argoff, C. E., Huygen, F. J. P. M., & Zundert, J. H. M. V. (2023) · Pain Practice · doi:10.1111/papr.13308 · Cited by 17
Linder, T., Dressler‐Steinbach, I., Wegener, S., Schellong, K., Schmidt, S., Eppel, D., Monod, C., Heinzl, F., Redling, K., Winzeler, B. F., et al. (2025) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(25)00288-8 · Cited by 23
Patel, S. B., Belalcazar, L. M., Afreen, S., Balderas, R., Hegele, R. A., Karpe, F., Ponte-Negretti, C. I., & Rajpal, A. (2025) · Endocrine Practice · doi:10.1016/j.eprac.2025.07.014 · Cited by 21
Self-citationThe Impact of Physical Activity in Patients With Type 2 Diabetes
Bassin, S. R., & Srinath, R. (2025) · American Journal of Lifestyle Medicine · doi:10.1177/15598276231180541 · Cited by 17
Yu, J., Ke, L., Zhou, J., Ding, C., Yang, H., Yan, D., & Yu, C. (2023) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s420253 · Cited by 16
“In fact, in recent years, the American Diabetes Association (ADA) has defined DR as a highly tissue-specific neurovascular complication.(4) A recent study found that DR occurrence may be related to the abnormal polyol metabolic pathway, the accumulation of protein nonenzymatic glycosylation products, the activation of…”
BackgroundFrías, J. P. (2023) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2023.2184796 · Cited by 18
“Over the past several years, the prominence of GLP-1 RAs in evidence-based T2D treatment guidelines has increased significantly [6,7].”
BackgroundTang, F.-Y., Guo, X.-T., Zhang, L., Yuan, L., Gan, T., Wang, M., Chen, X., Feng, C.-C., Qin, Y., Li, J., et al. (2023) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2023.110996 · Cited by 17
Khan, M. S., & Lea, J. P. (2024) · BMC Nephrology · doi:10.1186/s12882-024-03652-5 · Cited by 17
“GLP-1 RAs and SGLT2is exhibit different mechanisms that affect glucose metabolism; consequently, GLP-1 RAs are typically added to current antiglycemic treatments if there is ongoing hyperglycemia despite treatment and after taking patient factors into account [18, 84].”
BackgroundMethodInfluentialTanaka, M., Kawakami, A., Sakagami, K., Terai, T., & Ito, H. (2024) · Health and Quality of Life Outcomes · doi:10.1186/s12955-024-02247-w · Cited by 16
Samson, S. L., Vellanki, P., Blonde, L., Hirsch, I. B., Hoang, T. D., Isaacs, S. D., Izuora, K. E., Wang, C. C. L., Ooi, C. P., Padilla, B. I., et al. (2026) · Endocrine Practice · doi:10.1016/j.eprac.2026.01.006 · Cited by 29
Self-citationSGLT2 inhibitors reduce the risk of renal failure in CKD stage 5 patients with Type 2 DM
Huang, B., Yen, C., Wu, C., Tsai, C., Chen, J., Hsiao, C.-C., Chen, Y., Hsieh, I.-C., & Yang, H. (2025) · Scientific Reports · doi:10.1038/s41598-024-81973-z · Cited by 14
“Thus, recent guidelines of T2DM treatment have classified SGLT2 inhibitors as the initial option, especially when the primary objective is to prevent chronic kidney disease 12 .”
Moreno, Ó., Reyes‐García, R., Pardo, I. M., López-Martínez, M., & Soler, M. J. (2024) · Clinical Kidney Journal · doi:10.1093/ckj/sfae039 · Cited by 15
“In the context of ABCD, a minimum threshold of > 5%– ≥ 10% is required to have a positive impact on glycaemia, BP and lipids, and WL of ≥ 15% may help to mitigate other ABCD complications [58 ].”
BackgroundMethodGuldemond, N. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15476 · Cited by 17
“…professionals in healthcare and social care organizations who aim to prevent health issues, improve outcomes and reduce complications related to DM. 29 The procedures for assessing patient needs do not always capture the variety of needs at different stages of the disease and in various contexts,…”
BackgroundGlycated Hemoglobin A1c Time in Range and Dementia in Older Adults With Diabetes
UNDERWOOD, P. C., Zhang, L., Mohr, D. C., Prentice, J. C., Nelson, R. E., Budson, A. E., & Conlin, P. R. (2024) · JAMA Network Open · doi:10.1001/jamanetworkopen.2024.25354 · Cited by 20
Lee, J. Y., Lee, J.-H., Jung, E.-J., et al. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-025-02805-6 · Cited by 13
“Accordingly, the American Diabetes Association updated its guidelines in 2022 to recommend SGLT-2 inhibitors as first-line treatment options for patients with heart and kidney disease [4].”
Glycemic Targets and Prevention of Complications
Tsushima, Y., & Galloway, N. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae776 · Cited by 15
Continuous Glucose Monitoring for Hyperglycemia in Critically Ill Patients
Franck, A. J., Hendrickson, A. L., Telford, E. D., Davids, B. L., Casanova, I. M., Rosen, A. N., Hadigal, S., & Ross, R. C. (2025) · CHEST Journal · doi:10.1016/j.chest.2025.02.006 · Cited by 15
Argoff, C. E., Armstrong, D. G., KAGAN, Z. B., Jaasma, M. J., Bharara, M., Bradley, K., Caraway, D. L., Petersen, E., & for Investigators (2024) · Journal of Diabetes Science and Technology · doi:10.1177/19322968231222271 · Cited by 14
“AACE, American Association of Clinical Endocrinology; ADA, American Diabetes Association; CMM, conventional medical management; LOPS, loss of protective sensation; PDN, painful diabetic neuropathy; RCT, randomized controlled trial; SCS, spinal cord stimulation.”
InfluentialBlock, C. E. M. D., Peleshok, J. C., Wilding, J. P. H., Kwan, A. Y. M., Rasouli, N., Maldonado, J. M., Wysham, C., Liu, M., Aleppo, G., & Benneyworth, B. D. (2024) · Diabetes Therapy · doi:10.1007/s13300-024-01660-0 · Cited by 15
Garvey, W. T., Cohen, R. M., Butera, N. M., Kazemi, E. J., Younes, N., Rosin, S. P., Suratt, C. E., Ahmann, A., Hollander, P. A., Krakoff, J. A., et al. (2024) · Diabetes Care · doi:10.2337/dc23-1782 · Cited by 14
Self-citationMeng, Z., Xu, C., Liu, H., Gao, X., Li, X., Lin, W., Ma, X., Yang, C., Hao, M., Zhao, K., et al. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1272112 · Cited by 13
Freynhagen, R., Baron, R., Huygen, F. J. P. M., & Perrot, S. (2025) · PAIN Reports · doi:10.1097/pr9.0000000000001235 · Cited by 14
“…properties, clinical efficacy, and favourable safety/tolerability profile, the guidelines from the American Association of Clinical Endocrinology 11 and Clinical Compendia American Diabetes Association 49 also suggest it as a first-line treatment for PDPN. Capsaicin, the active ingredient of…”
Khartabil, N., & Avoundjian, A. (2025) · Genes · doi:10.3390/genes16010107 · Cited by 13
Makunts, T., Joulfayan, H., & Abagyan, R. A. (2024) · JMIRx Med · doi:10.2196/55976 · Cited by 15
“The American Association of Clinical Endocrinology and the American Diabetes Association recommend GLP-1 RAs for patients with T2DM who have chronic kidney disease, atherosclerotic cardiovascular disease risk, or obesity [6,7].”
BackgroundDiabetes Technology in People with Type 2 Diabetes: Novel Indications
Agarwal, S., Galindo, R. J., Shah, A. V., & Abreu, M. (2024) · Current Diabetes Reports · doi:10.1007/s11892-024-01536-4 · Cited by 12
Self-citationAktürk, H. K. (2024) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2023.0476 · Cited by 13
“10,11 However, its use is still limited due to cost and access in developing countries.”
The Role of Ultra-Rapid-Acting Insulin Analogs in Diabetes: An Expert Consensus
Giorgino, F., Battelino, T., Bergenstal, R. M., Forst, T. M., Green, J. B., Mathieu, C., Rodbard, H. W., Schnell, O., & Wilmot, E. G. (2023) · Journal of Diabetes Science and Technology · doi:10.1177/19322968231204584 · Cited by 17
Aydınyılmaz, F., Özbeyaz, N. B., Gulıyev, İ., Algül, E., Şahan, H. F., & Kalkan, K. (2023) · Angiology · doi:10.1177/00033197231185204 · Cited by 13
Metadata
- Authors
- Blonde, L., Umpierrez, G. E., Reddy, S. S., McGill, J. B., Berga, S. L., Bush, M., Chandrasekaran, S., DeFronzo, R. A., Einhorn, D., Galindo, R. J., Gardner, T. W., Garg, R., Garvey, W. T., Hirsch, I. B., Hurley, D. L., Izuora, K., Kosiborod, M., Olson, D., Patel, S. B., Pop-Busui, R., Sadhu, A. R., Samson, S. L., Stec, C., Tamborlane, W. V., Tuttle, K. R., Twining, C., Vella, A., Vellanki, P., & Weber, S. L.
- Affiliations
- Ochsner Health System (US)
- Emory University (US)
- Central Michigan University (US)
- Washington University in St. Louis (US)
- University at Buffalo, State University of New York (US)
- Cedars-Sinai Medical Center (US)
- The University of Texas at San Antonio (US)
- Scripps Whittier Diabetes Institute (US)
- University of Michigan (US)
- University of California, Los Angeles (US)
- University of Alabama at Birmingham (US)
- University of Washington (US)
- Mayo Clinic (US)
- University of Nevada, Las Vegas (US)
- Saint Luke's Hospital (US)
- Colorado Health Foundation (US)
- University of Cincinnati Medical Center (US)
- Houston Methodist (US)
- Mayo Clinic in Florida (US)
- American Association of Clinical Endocrinologists (US)
- Yale University (US)
- Maine Medical Center (US)
- Prisma Health (US)
- ORCID
- Blonde, Lawrence
- Umpierrez, Guillermo E.
- McGill, Janet B.
- Berga, Sarah L.
- Bush, Michael
- Chandrasekaran, Suchitra
- DeFronzo, Ralph A.
- Einhorn, Daniel
- Galindo, Rodolfo J.
- Gardner, Thomas W.
- Garg, Rajesh
- Garvey, W. Timothy
- Hirsch, Irl B.
- Hurley, Daniel L.
- Izuora, Kenneth
- Kosiborod, Mikhail
- Patel, Shailendra B.
- Sadhu, Archana R.
- Samson, Susan L.
- Tamborlane, William V.
- Tuttle, Katherine R.
- Vella, Adrian
- Vellanki, Priyathama
- Venue
- Endocrine Practice
- Publisher
- Elsevier BV
- Published
- 2022-10
- Volume
- 28
- Issue
- 10
- Pages
- 923-1049
- ISSN
- 1530-891X (ISSN-L)
- PMC
- PMC10200071
- OpenAlex
- W4291397630
- Cited by
- 507
- References
- 1,959
- Citations by year
- 2026: 95 · 2025: 119 · 2024: 150 · 2023: 134 · 2022: 9
- FWCI
- 76.49
- Type
- journal article
- Language
- en
- Update notices
- erratum (2023-01-01)
- Open access
- bronze
- doi.org
- Locations
- Endocrine Practice (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- National Institutes of Health (K23DK123384, P30DK111024)
- National Institute of Diabetes and Digestive and Kidney Diseases
- BP
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Education
- Keywords
- diabetes mellitus, comprehensive diabetes care, glycemic targets, blood glucose monitoring, diabetes complications, obesity, bariatric surgery, hypertension, dyslipidemia, diabetic retinopathy, diabetic neuropathy, diabetic nephropathy, cardiovascular disease, prediabetes, type 2 diabetes, type 1 diabetes, insulin therapy, hypoglycemia, diabetes in pregnancy, diabetes education, infertility, dietary supplements, social determinants of health, virtual care, cancer risk, pediatric diabetes care, depression, sleep medicine, team-based care
- MeSH terms
- Child, Diabetes Mellitus, Type 2, Endocrinology, Female, Humans, Hypoglycemic Agents, Insulin, Pregnancy, United States, Dyslipidemias
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-09-25 (prompt extract-v1).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
